H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 2329-0358

Home Page

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more


Published: 2020-03-31

Prophylaxis of Hepatitis B Virus (HBV) Re-Infection in Liver Transplantation: Is the Reappearance of Hepatitis B Surface Antigen (HBsAg) Significant?

Giuseppina Brancaccio, Giovanni B. Gaeta

(Department of Mental and Physical Health and Preventive Medicine, Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy)

Ann Transplant 2020; 25:e920969

DOI: 10.12659/AOT.920969


ABSTRACT: The recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) was in the past a primary cause of organ loss or mortality. Currently, post-OLT prophylaxis with anti-HBs immunoglobulins plus a nucleos(t)ide analogue has virtually abolished the risk of re-infection. Some studies have proposed to simplify prophylaxis by discontinuing immunoglobulins while continuing the analogue alone.
This review analysed the available studies, focusing on the recurrence of HBsAg in serum and its biological effects. In all, 16 studies were retrieved, mainly observational or retrospective, each enrolling 14 to 80 patients.
Our review of the literature found that HBsAg re-appeared in 0% to 24% of the patients, generally with HBV DNA undetectable in plasma. One study measured HBsAg using a new ultra-sensitive method, which could allow a reappraisal of the incidence of recurrence. This review discusses the role of HBV surface proteins in inducing hepatocellular carcinoma, particularly when mutations in the C-terminal occur that induce stop-codons that cause defects of secretion and retention of truncated protein S, resulting in direct cell toxicity and cancer.
The data on the suspension of immunoglobulins in the prophylaxis regimes of post-transplant re infection do not appear sufficiently robust for an extensive and safe application in clinical practice.

Keywords: Antiviral Agents, Hepatitis B, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Liver Transplantation



Related Articles (0)

Coming Soon...

Published: 2020-03-17

Optimizing Organ Donation: Expert Opinion from Austria, Germany, Spain and the U.K.


Fabian Becker, Keith J. Roberts, Miriam de Nadal, Michael Zink, Philipp Stiegler, Sonja Pemberger, Teresa Pont Castellana, Christian Kellner, Nick Murphy, Alexander Kaltenborn, Annette Tuffs, Volker Amelung, Christian Krauth, Janice Bayliss, Harald H. Schrem

Ann Transplant 2020; 25:e921727

DOI: 10.12659/AOT.921727

Published: 2020-03-13

Recipient Hepatic Tumor-Associated Immunologic Infiltrates Predict Outcomes After Liver Transplantation f...


Georgi Atanasov, Karoline Dino, Katrin Schierle, Corinna Dietel, Gabriela Aust, Johann Pratschke, Daniel Seehofer, Moritz Schmelzle, Hans-Michael Hau

Ann Transplant 2020; 25:e919414

DOI: 10.12659/AOT.919414